Species of tree Ginkgo biloba, commonly known as ginkgo (/ˈɡɪŋkoʊ, ˈɡɪŋkɡoʊ/ GINK-oh, -goh), also known as the maidenhair tree, and often misspelled "gingko" (see Etymology below) is a species of gymnosperm tree native to East Asia. It is the last living species in the order Ginkgoales, which first appeared over 290 million years ago. Fossils similar to the living species, belonging to the genus Ginkgo, extend back to the Middle Jurassic epoch about 170 million years ago. The tree was cultivated early in human history, remains commonly planted, and is widely regarded as a living fossil.
G. biloba is a long-lived, disease-resistant, dioecious tree with unique fan-shaped leaves, capable of clonal reproduction, and known for its striking yellow autumn foliage and resilience in disturbed environments. It was known historically as "silver fruit" or "white fruit" in Chinese and called "ginkgo" due to a centuries-old transcription error. It is closely related to cycads and characterized by unique seeds that resemble apricots but are not true fruits.
G. biloba, once widespread but thought extinct in the wild for centuries, is now commonly cultivated in East Asia, with some genetically diverse populations possibly representing rare wild survivors in southwestern China's mountainous regions. Some G. biloba trees have survived extreme events like the Hiroshima atomic bomb. Others show extreme longevity; G. biloba specimens have been measured in excess of 1,600 years, and the largest living trees are estimated to exceed 3,500 years. Today, it is widely planted in cities worldwide for its pollution tolerance and ornamental value.
G. biloba can pose health risks including potential carcinogenicity, allergic reactions, poisoning from seeds due to ginkgotoxin, drug interactions, and adverse effects such as bleeding and neurological symptoms, especially with excessive or improper use. G. biloba wood is valued for its durability and used in crafts and sake-making, while its seeds are popular in Asian cuisine despite health risks. Ginkgo-based products are widely marketed for cognitive benefits, although clinical research shows limited medical effectiveness except possibly for dementia, with approval in the European Union but not by the United States Food and Drug Administration.
Safety at a Glance
- Epilepsy caution. Those with seizure disorders or taking antiepileptic medications should consult a physician before ...
- Pregnancy. Ginkgo has antiplatelet effects and insufficient safety data in pregnancy. Use is not recommended during p...
- Toxicity: Ginkgo biloba has an excellent safety record at standardized doses (120–240 mg/day of EGb 761). It is registered as a...
- Start with a low dose and wait for onset before redosing
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
Oral
Duration
Oral
Total: 6 hrs – 10 hrsSubjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(5)
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Tinnitus— Phantom perception of ringing, buzzing, or hissing in the ears without external sound source, potent...
Pharmacology
Ginkgo biloba extract (standardized to EGb 761: 24% flavonoid glycosides, 6% terpene trilactones) contains two principal bioactive fractions: flavonoids (quercetin, kaempferol, isorhamnetin glycosides) and terpenoids (ginkgolides A, B, C, J, and bilobalide).
Ginkgolide B is the most pharmacologically distinctive component — a specific and potent competitive antagonist of platelet-activating factor (PAF) receptors. PAF is a phospholipid mediator involved in platelet aggregation, inflammation, and bronchoconstriction. Ginkgolide B inhibits PAF-induced platelet aggregation at nanomolar concentrations, improving microvascular blood flow — the primary rationale for its cognitive and vascular applications. Ginkgolide A also inhibits GABA-A receptors (specifically those containing alpha-1 subunits), which may contribute to reported memory-enhancing and slightly stimulating effects.
Bilobalide is neuroprotective through multiple mechanisms: inhibiting glutamate-induced excitotoxicity, protecting mitochondrial membrane potential, and providing anti-apoptotic signaling. It modulates GABA-A receptors and may reduce oxidative stress-induced mitochondrial dysfunction.
Flavonoids provide antioxidant protection through free radical scavenging (particularly superoxide and hydroxyl radicals) and chelation of pro-oxidant transition metals (iron, copper). They also modulate nitric oxide (NO) production, inhibit COX enzymes (anti-inflammatory), and upregulate Nrf2 pathway cytoprotective genes.
At the neurotransmitter level, Ginkgo increases cholinergic tone (enhancing acetylcholine release and reducing acetylcholinesterase activity in some models), modulates serotonin (5-HT2A agonism and serotonin reuptake modulation), and influences noradrenaline signaling. This broad neurotransmitter modulation makes precise pharmacological characterization complex.
Interactions
No documented interactions.
History
Ginkgo biloba is often called a "living fossil" — the sole surviving species of the Ginkgophyta division, a once-diverse group of plants dominant during the Triassic and Jurassic periods. Fossil evidence shows Ginkgo ancestors dating to 270 million years ago, and the species has remained morphologically nearly unchanged for 200 million years.
Ginkgo trees are native to eastern China and have been cultivated in Buddhist temple gardens for over 1,000 years. Traditional Chinese medicine used ginkgo seeds (bai guo) for respiratory conditions and kidney and bladder complaints, and ginkgo leaf preparations for memory, blood flow, and tinnitus — though these were distinct formulations from the modern standardized leaf extract.
Western scientific attention began in the 17th century when German botanist Engelbert Kaempfer introduced the species to Europe after encountering it in Japan. Ginkgo was successfully grown in European botanical gardens from 1730 onward and planted widely as an ornamental tree.
Modern pharmaceutical interest in Ginkgo leaf extract began at Willmar Schwabe GmbH in Germany in the 1960s, leading to the development of the standardized EGb 761 extract by the 1980s. Clinical trials in Germany established evidence for circulatory benefits in peripheral artery disease, and subsequent Alzheimer's disease research positioned Ginkgo as a potential cognitive protective agent.
The Ginkgo Evaluation of Memory (GEM) Study (2008, JAMA) and similar large randomized trials found that Ginkgo did not prevent dementia or Alzheimer's disease progression, dampening earlier enthusiasm. Ginkgo remains one of the top-selling dietary supplements globally, particularly in Germany, France, and China.
Harm Reduction
Use standardized extract. Ginkgo products vary enormously in quality. Look for EGb 761 (the research-standard German extract) or products standardized to 24% flavonol glycosides and 6% terpene lactones. Avoid crude leaf preparations or non-standardized products; ginkgolic acid levels in non-standardized products can be problematically high.
Bleeding risk management. Ginkgo should not be combined with anticoagulants (warfarin, heparin), antiplatelet drugs (aspirin, clopidogrel, ticagrelor), or high-dose NSAIDs without informing your physician. Stop Ginkgo at least 2 weeks before any elective surgery or procedure.
Epilepsy caution. Those with seizure disorders or taking antiepileptic medications should consult a physician before using Ginkgo and should strictly avoid any preparation containing ginkgo seeds.
Realistic expectations for cognition. The evidence for Ginkgo's cognitive benefits in healthy young adults is weak and inconsistent. Benefits are most clearly established in cognitive decline (particularly mild cognitive impairment and early dementia) and circulation-related conditions (peripheral artery disease, tinnitus with vascular cause). Do not expect dramatic nootropic effects in healthy young adults.
Pregnancy. Ginkgo has antiplatelet effects and insufficient safety data in pregnancy. Use is not recommended during pregnancy.
Patience. Clinical studies typically run 12–24 weeks for cognitive and circulatory effects. Short-term acute effects are subtle. Consistent daily use for several months is needed to evaluate efficacy.
Toxicity & Safety
Ginkgo biloba has an excellent safety record at standardized doses (120–240 mg/day of EGb 761). It is registered as a prescription medicine in Germany and France for cognitive decline and peripheral arterial disease, and has been used by millions of patients in clinical settings.
Antiplatelet effects represent the most clinically significant safety concern. By inhibiting PAF and reducing platelet aggregation, Ginkgo increases bleeding risk. This is particularly relevant in combination with anticoagulants (warfarin), antiplatelet drugs (aspirin, clopidogrel), or NSAIDs. Isolated case reports of spontaneous bleeding (including intracranial hemorrhage) in Ginkgo users have been documented, though causality is difficult to establish definitively. Discontinue Ginkgo 2 weeks before surgery.
Seizure risk: Both ginkgolide A (GABA-A antagonism) and ginkgo seeds (which contain the toxin 4-O-methylpyridoxine/ginkgotoxin) have been associated with seizure induction. Ginkgotoxin depletes pyridoxal phosphate (vitamin B6) and can cause epileptic seizures — this is primarily a risk from consuming ginkgo seeds/nuts, not standardized leaf extract, but some extract preparations with residual seed material carry this risk. Patients with epilepsy or those taking antiepileptic drugs should use with caution.
Ginkgolic acids (present in Ginkgo leaves but removed in EGb 761 processing) are allergenic and potentially mutagenic. Low-quality extracts with high ginkgolic acid content pose greater allergenic risk. Quality matters significantly.
Drug interactions: Ginkgo induces CYP2C19 and inhibits CYP3A4 to some degree, potentially affecting levels of anticoagulants, antiretrovirals, and some psychiatric medications.
At recommended doses, headache (often transient), GI upset, and dizziness are the most common side effects.
Addiction Potential
No addiction potential.
Tolerance
| Full | Not applicable — nutritional supplement |
| Half | N/A |
| Zero | N/A |
Cross-tolerances
Legal Status
This substance is not a controlled or scheduled substance in any major jurisdiction. It is widely available as a dietary supplement, food additive, or over-the-counter product in the United States, United Kingdom, European Union, Canada, and Australia. In the US, it falls under the Dietary Supplement Health and Education Act (DSHEA) of 1994 and is regulated by the FDA as a dietary supplement rather than a drug. Manufacturers are responsible for ensuring safety and accurate labeling, but pre-market approval is not required.
In the European Union, it is regulated under the Food Supplements Directive (2002/46/EC) and may be subject to maximum permitted levels set by individual member states. In the United Kingdom, it falls under the Food Supplements (England) Regulations 2003 and similar devolved legislation. In Australia, it is typically listed on the Australian Register of Therapeutic Goods (ARTG) as a complementary medicine or is available as a food product. In Canada, it may be classified as a Natural Health Product (NHP) requiring a product license from Health Canada.
No prescription is required in any of these jurisdictions, and there are no criminal penalties associated with possession, purchase, or use.
Tips (6)
Cycle Ginkgo Biloba usage to prevent tolerance and dependence. Most nootropics benefit from periodic breaks (e.g., 5 days on / 2 days off, or 3 weeks on / 1 week off) to maintain effectiveness.
Research potential interactions between Ginkgo Biloba and any medications or supplements you take. Nootropics can interact with prescription drugs in unexpected ways, particularly those affecting neurotransmitter systems.
Ginkgo biloba has significant blood-thinning properties. Do not combine it with anticoagulants like warfarin, aspirin, or NSAIDs without medical consultation. Discontinue use at least 2 weeks before any surgical procedure to reduce bleeding risk.
Keep a journal when starting Ginkgo Biloba to track cognitive effects, mood, sleep quality, and side effects. Nootropic effects are often subtle, and subjective tracking helps determine if a substance is genuinely beneficial for you.
Look for standardized extracts containing 24% flavone glycosides and 6% terpene lactones (the EGb 761 formulation used in clinical studies). Standard dose is 120-240mg daily, typically divided into 2-3 doses. Effects, if any, may take 4-6 weeks of consistent use to become noticeable.
The evidence for ginkgo biloba improving cognition in healthy young adults is weak. Most positive studies involve elderly populations with existing cognitive decline. If you are in your 20s-40s and cognitively healthy, the benefits are likely minimal. Consider it a long-term investment in vascular health rather than a nootropic.
Community Discussions (1)
See Also
References (2)
- Ginkgo Biloba - TripSit Factsheet
TripSit factsheet for Ginkgo Biloba
tripsit - Ginkgo Biloba - Wikipedia
Wikipedia article on Ginkgo Biloba
wikipedia